Interactions between antiepileptics and second-generation antipsychotics

被引:68
|
作者
de Leon, Jose [1 ,3 ]
Santoro, Vincenza [2 ]
D'Arrigo, Concetta [2 ]
Spina, Edoardo [2 ]
机构
[1] Univ Kentucky, Mental Hlth Res Ctr, Eastern State Hosp, Lexington, KY 40508 USA
[2] Univ Messina, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Messina, Italy
[3] Univ Granada, Inst Neurosci Psychiat & Neurosci Res Grp CTS 549, Granada, Spain
关键词
amisulpride; anticonvulsants; antipsychotics; aripiprazole; asenapine; bipolar disorder; carbamazepine; clozapine; drug interactions; eslicarbazepine; ethosuximide; felbamate; gabapentin; iloperidone; lacosamide; lamotrigine; levetiracetam; lurasidone; olanzapine; oxcarbazepine; paliperidone; pharmacokinetics; phenobarbital; phenytoin; pregabalin; primidone; quetiapine; retigabine; risperidone; rufinamide; stiripentol; tiagabine; topiramate; valproate; vigabatrin; ziprasidone; zonisamide; STEADY-STATE PHARMACOKINETICS; DRUG-MONITORING SERVICE; PLASMA CLOZAPINE CONCENTRATIONS; RANDOMIZED CONTROLLED-TRIAL; OLANZAPINE SERUM CONCENTRATIONS; MAJOR DEPRESSIVE DISORDER; PREGNANE-X RECEPTOR; BIPOLAR I DISORDER; OF-THE-LITERATURE; VALPROIC ACID;
D O I
10.1517/17425255.2012.660918
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Pharmacokinetic and pharmacodynamic drug interactions (DIs) can occur between antiepileptics (AEDs) and second-generation antipsychotics (SGAPs). Some AED and SGAP pharmacodynamic mechanisms are poorly understood. AED--SGAP combinations are used for treating comorbid illnesses or increasing efficacy, particularly in bipolar disorder. Areas covered: This article provides a comprehensive review of the interactions between antiepileptics and second-generation antipsychotics. The authors cover pharmacokinetic AED--SGAP DI studies, the newest drug pharmacokinetics in addition to the limited pharmacodynamic DI studies. Expert opinion: Dosing correction factors and measuring SGAP levels can help to compensate for the inductive properties of carbamazepine, phenytoin, phenobarbital and primidone. Further studies are needed to establish the clinical relevance of combining: i) AED strong inducers with amisulpride, asenapine, iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole, asenapine, clozapine and olanzapine; iii) high doses of oxcarbazepine (1500 mg/day) or topiramate (>= 400 mg/day) with aripiprazole, lurasidone, quetiapine, risperidone, asenapine and olanzapine. Two pharmacodynamic DIs are beneficial: i) valproate-SGAP combinations may have additive effects in bipolar disorder, ii) combining topiramate or zonisamide with SGAPs may decrease weight gain. Three pharmacodynamic DIs contributing to decreased safety are common: sedation, weight gain and swallowing disturbances. A few AED--SGAP combinations may increase risk for osteoporosis or nausea. Three potentially lethal but rare pharmacodynamic DIs include pancreatitis, agranulocytosis/leukopenia and heat stroke. The authors believe that collaboration is needed from drug agencies and pharmaceutical companies, the clinicians using these combinations, researchers with expertise in meta-analyses, grant agencies, pharmacoepidemiologists and DI pharmacologists for future progression in this field.
引用
收藏
页码:311 / 334
页数:24
相关论文
共 50 条
  • [11] Tardive dyskinesia and second-generation antipsychotics
    Ross, DE
    AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (02): : 405 - 405
  • [13] Second-generation antipsychotics - Aripiprazole revisited
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1219): : 81 - 82
  • [14] Second-Generation Antipsychotics and Suicide: A Commentary
    Zuschlag, Zachary D.
    JOURNAL OF CLINICAL PSYCHIATRY, 2021, 82 (05)
  • [15] Assessing the Costs of Second-Generation Antipsychotics
    Pfeiffer, Paul N.
    Valenstein, Marcia
    PSYCHIATRIC SERVICES, 2012, 63 (03) : 199 - 199
  • [16] Second-generation antipsychotics and pregnancy complications
    Maria Ellfolk
    Maarit K. Leinonen
    Mika Gissler
    Anna-Maria Lahesmaa-Korpinen
    Leena Saastamoinen
    Marja-Leena Nurminen
    Heli Malm
    European Journal of Clinical Pharmacology, 2020, 76 : 107 - 115
  • [17] Diabetes and second-generation (atypical) antipsychotics
    Chabroux, S.
    Haffen, E.
    Penfornis, A.
    ANNALES D ENDOCRINOLOGIE, 2009, 70 (04) : 202 - 210
  • [18] Second-generation antipsychotics and metabolic syndrome
    Farines, Magali
    Alberto-Gondouin, Marie-Christine M. C.
    PHARMACY WORLD & SCIENCE, 2008, 30 (05): : 720 - 720
  • [19] Second-generation antipsychotics and VTE risk
    Deloughery, Emma P.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (02) : 257 - 259
  • [20] Second-generation antipsychotics and pregnancy complications
    Elfolk, Maria
    Leinonen, Maarit K.
    Gissler, Mika
    Lahesmaa-Korpinen, Anna-Maria
    Saastamoinen, Leena
    Nurminen, Marja-Leena
    Malm, Heli
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (01) : 107 - 115